Untitled

Ochang Branch InstituteTherapeutic AntibodyResearch CenterACHIEVEMENTSDiscovery of therapeutic target PAUF for pancreatic cancer therapies and developmentof human anti-PAUF monoclonal antibodiesThe mining of a DNA microarray expression database allowed identification of PAUF asoverexpressed in pancreatic cancer and playing an important role in tumor progressionand metastasis. Human antibodies targeting PAUF inhibited tumor growth in nude micebearing human pancreatic cancer.RESEARCHERSSang Seok Koh sskoh@kribb.re.krStudies on targeted therapeutics through cancergenomicsMechanistic investigation of novel metastatic factorsJin-San Yoo hottac@kribb.re.krDevelopment of antibody-based therapeuticsEngineering of antibodies and beyond for clinicalapplicationSemi Kim semikim@kribb.re.krIdentification/validation of novel therapeutic targets incancer development and metastasisDevelopment of anti-cancer biologics drugsJeong-ki Min jekmin@kribb.re.krAngiogenesisStudies on the functions of cancer markersJuyeon Jung jjung@kribb.re.krProtein engineeringTherapeutic antibody developmentRESEARCH AREASCancer cell biologyTumor progression and metastasisApoptosisIntracellular signalingStem cellsDiscovery and validation of drug targets for antibodybasedcancer therapiesDiscovery of drug targets through genomics andantibody approachesStudies of the role of identified targets in tumorprogressionValidation of drug targets as anti-cancer agentsDevelopment of therapeutic antibodiesDevelopment of therapeutic antibodies, such as humanmonoclonal antibodies and humanized antibodiesOptimization of therapeutic antibodies through affinitymaturationConstruction of mammalian cell lines, producingtherapeutic antibodies and proteinsProduction and purification of therapeutic antibodies andproteinsIn vitro and in vivo study of therapeutic antibodies andproteinsDirector Sang Seok KohT +82-42-860-4125F + 82-42-860-4149E sskoh@kribb.re.krDiscovery of therapeutic target TMPRSS4 for cancer therapies and development ofhuman anti-TMPRSS4 monoclonal antibodiesA Novel type II transmembrane serine protease TMPRSS4 was identified andcharacterized as a cancer therapeutic target. The new protease proved to be highlyup-regulated in lung cancer tissues and is associated with the invasiveness, motility, andcell-matrix adhesion of cancer cells. Human monoclonal antibodies to TMPRSS4 havebeen developed and their anti-cancer properties are under investigation.SELECTED PUBLICATIONSSemi Kim (Co-corresponding) Carcinogenesis. 31(4):597-606.TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulationof integrin alpha5 and its signaling pathwaysJeong-Ki Min (Co-first) Circ Res. 107(7):871-6.Receptor activator of nuclear factor kappaB ligand is a novel inducer of tissue factor inmacrophagesJeong-Ki Min (First) Clin Cancer Res. 16(14):3571-80.L1 cell adhesion molecule is a novel therapeutic target in intrahepaticcholangiocarcinomaSang Seok Koh (Corresponding) Int J Cancer. 127(6):1308-20.The protease inhibitor, elafin, induces p53-dependent apoptosis in human melanoma cellsSang Seok Koh (Co-corresponding) Oncogene. 29(1):56-67.PAUF functions in the metastasis of human pancreatic cancer cells and upregulatesCXCR4 expressionOur goal is to discover new targets for antibody-based cancer therapies and to develop therapeutic antibodies.We also study the molecular mechanisms of cancer progression and validate anti-cancer drug targets.56 KRIBB Annual Report 2010KRIBB Annual Report 2010 57